Breaking News

Ventrus Contracts inVentiv, Almac for Phase III Trial

Ventrus Biosciences has selected inVentiv Clinical Solutions to manage its Phase III trial with Iferanserin in development for the treatment of hemorrhoids.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ventrus Biosciences has selected inVentiv Clinical Solutions to manage its Phase III trial with Iferanserin in development for the treatment of hemorrhoids. Ventrus has selected Almac Group to provide electronic patient-reported outcomes solutions. Ventrus plans to initiate its first Phase III trial in 2011 and expects data in 1Q12. The study will enroll 400 patients who will be randomized to receive placebo or Iferanserin. The primary endpoint is cessation of bleeding. Russell Ellison, ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters